Key Updates in the Management of Small Cell Lung Cancer
Ryan Haumschild, PharmD, MS, MBA; Anne Chiang, MD, PhD; Afshin Dowlati, MD; Jacob Sands, MD; and Wade Iams, MD, explore recent advances in small cell lung cancer (SCLC) management, discussing staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery.
Episodes
September 27th 2024EP. 1: Introduction: Risk Factors and Characteristics Defining SCLC
Panelists discuss how small cell lung cancer (SCLC) differs from non–small cell lung cancer in terms of staging, epidemiology, risk factors, prevention strategies, and prognosis, while also exploring the distinctions between limited-stage and extensive-stage SCLC and considering potential improvements in staging practices.
September 27th 2024EP. 2: Established Multidisciplinary Therapies for SCLC
Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.
